SPNS3 Inhibitors
SPNS3 inhibitors Cyclosporin A and BAPTA-AM can modulate calcium-related signaling. Probenecid disrupts metabolite transport, while verapamil affects calcium channel activity. Genistein's inhibition of tyrosine kinases and NF449's antagonism of P2X receptors can alter broad signaling networks. Miconazole's effect on cytochrome P450 enzymes impacts lipid metabolism, and GW4869's inhibition of sphingomyelinase affects sphingolipid signaling. ML-7's inhibition of myosin light chain kinase can influence cytoskeletal functions, and LY294002 disrupts PI3K signaling pathways. PD98059 affects MAPK signaling, and W-7 disrupts calmodulin-dependent processes.
Collectively, these agents demonstrate how diverse chemical inhibitors can indirectly affect the activity of a protein by targeting a variety of cellular components and pathways. The alteration of these pathways can modulate the function of proteins that are associated with or regulated by these pathways. The range of these inhibitors' targets includes enzymes, ion channels, transporters, and receptors, reflecting the myriad of processes that can be influenced to modulate protein function indirectly.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Inhibits calcineurin, which could affect downstream signaling pathways related to ion homeostasis and transport, potentially influencing SPNS3 activity if it were associated with such processes. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
Chelates intracellular calcium, which may disrupt calcium-dependent signaling pathways that could regulate SPNS3 if the protein is part of such pathways. | ||||||
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $27.00 $38.00 $98.00 $272.00 | 28 | |
Inhibits organic anion transporters and may disrupt cellular substrate levels that could alter SPNS3 activity if it interacts with metabolites. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Calcium channel blocker that could interfere with calcium signaling, potentially influencing SPNS3 activity if the protein is calcium-sensitive. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Inhibits tyrosine kinases, which could modify signaling pathways that regulate SPNS3 if it is phosphorylated by such kinases. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $199.00 $460.00 $1479.00 | 1 | |
P2X receptor antagonist that could alter purinergic signaling, which may indirectly affect SPNS3 if the protein is involved in this pathway. | ||||||
Miconazole | 22916-47-8 | sc-204806 sc-204806A | 1 g 5 g | $65.00 $157.00 | 2 | |
Inhibits cytochrome P450 enzymes, which could alter lipid metabolism and signaling, potentially affecting SPNS3 activity if it interacts with lipid substrates or products. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
Neutral sphingomyelinase inhibitor that could alter sphingolipid signaling, potentially affecting SPNS3 if it is involved in the metabolism or response to sphingolipids. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
Inhibits myosin light chain kinase, which could affect cytoskeletal dynamics and signaling, influencing SPNS3 activity if the protein interacts with the cytoskeleton. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, disrupting phosphoinositide signaling, which could affect SPNS3 if it is associated with this pathway. | ||||||